Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: a comprehensive review
Breast cancer (BC) is the most common cancer in women and poses a serious threat to their
health. Despite familiarity with factors affecting its etiology, initiation, progression, treatment …
health. Despite familiarity with factors affecting its etiology, initiation, progression, treatment …
Resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer
ER Scheidemann, AN Shajahan-Haq - International Journal of Molecular …, 2021 - mdpi.com
Estrogen receptor-positive (ER+) breast cancer is the most common form of breast cancer.
Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these …
Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these …
Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer
A Mittal, C Molto Valiente, F Tamimi, I Schlam… - Cancers, 2023 - mdpi.com
Simple Summary There are limited treatment options beyond chemotherapy for patients with
hormone receptor positive metastatic breast cancer after progression on first line therapy …
hormone receptor positive metastatic breast cancer after progression on first line therapy …
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer
Y Li, W Li, C Gong, Y Zheng… - Therapeutic …, 2021 - journals.sagepub.com
Introduction: Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i)
are standard treatment options for hormone receptor positive (HR+)/human epidermal …
are standard treatment options for hormone receptor positive (HR+)/human epidermal …
Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial
A McCartney, M Bonechi, F De Luca, C Biagioni… - Clinical cancer …, 2020 - AACR
Abstract Purpose: Thymidine kinase 1 (TK1) is downstream to the CDK4/6 pathway, and TK
activity (TKa) measured in blood is a dynamic marker of outcome in patients with advanced …
activity (TKa) measured in blood is a dynamic marker of outcome in patients with advanced …
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç… - BMC cancer, 2023 - Springer
Background There is no standard treatment recommended at category 1 level in
international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor …
international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor …
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
I Migliaccio, M Bonechi, A McCartney… - Cancer Treatment …, 2021 - Elsevier
Abstract CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy are the
mainstay of treatment for patients with hormone receptor-positive, HER2 negative …
mainstay of treatment for patients with hormone receptor-positive, HER2 negative …
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the …
F Galardi, F De Luca, C Biagioni, I Migliaccio… - Breast Cancer …, 2021 - Springer
Abstract Background Circulating tumor cells (CTCs) are prognostic in patients with
advanced breast cancer (ABC). However, no data exist about their use in patients treated …
advanced breast cancer (ABC). However, no data exist about their use in patients treated …
[HTML][HTML] First-and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: a real-world study
D Basile, L Gerratana, C Corvaja, G Pelizzari… - The Breast, 2021 - Elsevier
Background Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i)
represents the standard treatment for luminal-metastatic breast cancer (MBC). However …
represents the standard treatment for luminal-metastatic breast cancer (MBC). However …
Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world …
R Palumbo, R Torrisi, F Sottotetti… - Therapeutic …, 2021 - journals.sagepub.com
Background: The CDK4/6 inhibitor palbociclib combined with endocrine therapy (ET) has
proven to prolong progression-free survival (PFS) in women with hormone receptor-positive …
proven to prolong progression-free survival (PFS) in women with hormone receptor-positive …